Do analysts rate XLO or ADAG?

Adagene has a consensus target price of $9.50, indicating a potential upside of 179.41%. Given Adagene's stronger consensus rating and higher possible upside, analysts plainly believe Adagene is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Adagene 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has better valuation and earnings, XLO or ADAG?

Adagene has lower revenue, but higher earnings than Xilio Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xilio Therapeutics $43.77M 1.34 -$35.04M -$1.64 N/A Adagene $7.67M 29.28 -$17.61M N/A N/A

Do analysts prefer GLSI or XLO?

Greenwich LifeSciences currently has a consensus target price of $69.00, suggesting a potential upside of 346.60%. Given Greenwich LifeSciences' stronger consensus rating and higher probable upside, research analysts clearly believe Greenwich LifeSciences is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenwich LifeSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend XLO or TARA?

Protara Therapeutics has a consensus target price of $26.25, suggesting a potential upside of 587.17%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Protara Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Do analysts rate XLO or IPHA?

Innate Pharma has a consensus price target of $6.67, indicating a potential upside of 256.51%. Given Innate Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Innate Pharma is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Innate Pharma 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has stronger valuation and earnings, XLO or IPHA?

Xilio Therapeutics has higher revenue and earnings than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xilio Therapeutics $43.77M 1.34 -$35.04M -$1.64 N/A Innate Pharma $10.19M 20.50 -$55.64M N/A N/A

Do analysts recommend ABOS or XLO?

Acumen Pharmaceuticals presently has a consensus target price of $8.00, indicating a potential upside of 173.97%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Acumen Pharmaceuticals is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acumen Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Xilio Therapeutics (XLO) Competitors

$8.93 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$9.09 +0.16 (+1.74%)

As of 09/11/2026 06:59 PM Eastern

Compare

XLO vs. ADAG, GLSI, TARA, IPHA, and ABOS

Should you buy Xilio Therapeutics stock or one of its competitors? Xilio Therapeutics's main competitors and comparable companies include Adagene (ADAG), Greenwich LifeSciences (GLSI), Protara Therapeutics (TARA), Innate Pharma (IPHA), and Acumen Pharmaceuticals (ABOS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Xilio Therapeutics compare to Adagene?

Xilio Therapeutics (NASDAQ:XLO) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

In the previous week, Adagene had 9 more articles in the media than Xilio Therapeutics. MarketBeat recorded 10 mentions for Adagene and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 1.87 beat Adagene's score of 0.31 indicating that Xilio Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Xilio Therapeutics	Very Positive
Adagene	Neutral

Xilio Therapeutics has a beta of -0.14, suggesting that its share price is 114% less volatile than the broader market. Comparatively, Adagene has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by insiders. Comparatively, 21.2% of Adagene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Adagene has a consensus target price of $9.50, indicating a potential upside of 179.41%. Given Adagene's stronger consensus rating and higher possible upside, analysts plainly believe Adagene is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Adagene has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -34.06%. Adagene's return on equity of 0.00% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-34.06%	-71.99%	-20.43%
Adagene	N/A	N/A	N/A

Adagene has lower revenue, but higher earnings than Xilio Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.34	-$35.04M	-$1.64	N/A
Adagene	$7.67M	29.28	-$17.61M	N/A	N/A

Summary

Adagene beats Xilio Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Xilio Therapeutics compare to Greenwich LifeSciences?

Greenwich LifeSciences (NASDAQ:GLSI) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

Greenwich LifeSciences has higher earnings, but lower revenue than Xilio Therapeutics. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.54	N/A
Xilio Therapeutics	$43.77M	1.34	-$35.04M	-$1.64	N/A

In the previous week, Greenwich LifeSciences and Greenwich LifeSciences both had 1 articles in the media. Greenwich LifeSciences' average media sentiment score of 1.89 beat Xilio Therapeutics' score of 1.87 indicating that Greenwich LifeSciences is being referred to more favorably in the media.

Company	Overall Sentiment
Greenwich LifeSciences	Very Positive
Xilio Therapeutics	Very Positive

4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by insiders. Comparatively, 7.5% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Greenwich LifeSciences currently has a consensus target price of $69.00, suggesting a potential upside of 346.60%. Given Greenwich LifeSciences' stronger consensus rating and higher probable upside, research analysts clearly believe Greenwich LifeSciences is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Greenwich LifeSciences has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.14, suggesting that its stock price is 114% less volatile than the broader market.

Greenwich LifeSciences has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -34.06%. Xilio Therapeutics' return on equity of -71.99% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-793.81%	-295.32%
Xilio Therapeutics	-34.06%	-71.99%	-20.43%

Summary

Greenwich LifeSciences beats Xilio Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Xilio Therapeutics compare to Protara Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Protara Therapeutics (NASDAQ:TARA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

Protara Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -34.06%. Protara Therapeutics' return on equity of -41.72% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-34.06%	-71.99%	-20.43%
Protara Therapeutics	N/A	-41.72%	-38.78%

Protara Therapeutics has a consensus target price of $26.25, suggesting a potential upside of 587.17%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Protara Therapeutics had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 2 mentions for Protara Therapeutics and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 1.87 beat Protara Therapeutics' score of 0.94 indicating that Xilio Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Xilio Therapeutics	Very Positive
Protara Therapeutics	Positive

Xilio Therapeutics has higher revenue and earnings than Protara Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.34	-$35.04M	-$1.64	N/A
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A

Xilio Therapeutics has a beta of -0.14, indicating that its stock price is 114% less volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 7.5% of Xilio Therapeutics shares are held by company insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Protara Therapeutics beats Xilio Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Xilio Therapeutics compare to Innate Pharma?

Xilio Therapeutics (NASDAQ:XLO) and Innate Pharma (NASDAQ:IPHA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Xilio Therapeutics has higher revenue and earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.34	-$35.04M	-$1.64	N/A
Innate Pharma	$10.19M	20.50	-$55.64M	N/A	N/A

Innate Pharma has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -34.06%. Innate Pharma's return on equity of 0.00% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-34.06%	-71.99%	-20.43%
Innate Pharma	N/A	N/A	N/A

54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 7.5% of Xilio Therapeutics shares are held by company insiders. Comparatively, 31.9% of Innate Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Innate Pharma had 5 more articles in the media than Xilio Therapeutics. MarketBeat recorded 6 mentions for Innate Pharma and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 1.87 beat Innate Pharma's score of 0.81 indicating that Xilio Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Xilio Therapeutics	Very Positive
Innate Pharma	Positive

Innate Pharma has a consensus price target of $6.67, indicating a potential upside of 256.51%. Given Innate Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Innate Pharma is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Xilio Therapeutics has a beta of -0.14, suggesting that its stock price is 114% less volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

Summary

Innate Pharma beats Xilio Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Xilio Therapeutics compare to Acumen Pharmaceuticals?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Acumen Pharmaceuticals presently has a consensus target price of $8.00, indicating a potential upside of 173.97%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Acumen Pharmaceuticals is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Xilio Therapeutics has higher revenue and earnings than Acumen Pharmaceuticals. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A
Xilio Therapeutics	$43.77M	1.34	-$35.04M	-$1.64	N/A

Acumen Pharmaceuticals has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -34.06%. Xilio Therapeutics' return on equity of -71.99% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%
Xilio Therapeutics	-34.06%	-71.99%	-20.43%

Acumen Pharmaceuticals has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.14, indicating that its stock price is 114% less volatile than the broader market.

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Comparatively, 7.5% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Acumen Pharmaceuticals had 2 more articles in the media than Xilio Therapeutics. MarketBeat recorded 3 mentions for Acumen Pharmaceuticals and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 1.87 beat Acumen Pharmaceuticals' score of 0.63 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Acumen Pharmaceuticals	Positive
Xilio Therapeutics	Very Positive

Summary

Acumen Pharmaceuticals beats Xilio Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Xilio Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XLO vs. The Competition

Export

Metric	Xilio Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$58.76M	$3.85B	$7.15B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.17%
P/E Ratio	N/A	14.18	274.94	25.36
Price / Sales	1.34	1,374.99	686.57	116.78
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	1.22	15.12	10.33	6.20
Net Income	-$35.04M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-0.78%	-4.34%	-3.32%	-2.35%
1 Month Performance	-0.89%	0.54%	-0.53%	-3.23%
1 Year Performance	-13.41%	40.74%	23.51%	8.79%

Xilio Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XLO Xilio Therapeutics	0.2173 of 5 stars	$8.93 flat	N/A	-13.4%	$58.76M	$43.77M	N/A	70	Positive News
ADAG Adagene	3.8754 of 5 stars	$3.49 -2.5%	$10.00 +186.5%	+51.8%	$236.47M	$9.29M	N/A	260	News Coverage Analyst Forecast
GLSI Greenwich LifeSciences	2.7064 of 5 stars	$15.90 -0.3%	$69.00 +334.0%	+37.6%	$234.11M	N/A	N/A	3	Positive News
TARA Protara Therapeutics	1.8147 of 5 stars	$3.89 -1.3%	$26.25 +574.8%	+21.7%	$232.83M	N/A	N/A	30	Positive News
IPHA Innate Pharma	4.1065 of 5 stars	$2.05 -1.4%	$6.67 +225.2%	-6.5%	$232.38M	$2.79M	N/A	220	News Coverage Positive News Upcoming Earnings Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XLO) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xilio Therapeutics (XLO) Competitors

XLO vs. ADAG, GLSI, TARA, IPHA, and ABOS

How does Xilio Therapeutics compare to Adagene?

Summary

How does Xilio Therapeutics compare to Greenwich LifeSciences?

Summary

How does Xilio Therapeutics compare to Protara Therapeutics?

Summary

How does Xilio Therapeutics compare to Innate Pharma?

Summary

How does Xilio Therapeutics compare to Acumen Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO vs. The Competition

Xilio Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xilio Therapeutics (XLO) Competitors

XLO vs. ADAG, GLSI, TARA, IPHA, and ABOS

How does Xilio Therapeutics compare to Adagene?

Does the media refer more to XLO or ADAG?

Which has more volatility and risk, XLO or ADAG?

Do insiders & institutionals believe in XLO or ADAG?

Do analysts rate XLO or ADAG?

Is XLO or ADAG more profitable?

Which has better valuation and earnings, XLO or ADAG?

Summary

How does Xilio Therapeutics compare to Greenwich LifeSciences?

Which has stronger valuation & earnings, GLSI or XLO?

Does the media prefer GLSI or XLO?

Do insiders and institutionals hold more shares of GLSI or XLO?

Do analysts prefer GLSI or XLO?

Which has more volatility and risk, GLSI or XLO?

Is GLSI or XLO more profitable?

Summary

How does Xilio Therapeutics compare to Protara Therapeutics?

Is XLO or TARA more profitable?

Do analysts recommend XLO or TARA?

Does the media favor XLO or TARA?

Which has preferable valuation & earnings, XLO or TARA?

Which has more volatility and risk, XLO or TARA?

Do institutionals and insiders hold more shares of XLO or TARA?

Summary

How does Xilio Therapeutics compare to Innate Pharma?

Which has stronger valuation and earnings, XLO or IPHA?

Is XLO or IPHA more profitable?

Do institutionals & insiders have more ownership in XLO or IPHA?

Does the media favor XLO or IPHA?

Do analysts rate XLO or IPHA?

Which has more volatility and risk, XLO or IPHA?

Summary

How does Xilio Therapeutics compare to Acumen Pharmaceuticals?

Do analysts recommend ABOS or XLO?

Which has higher earnings and valuation, ABOS or XLO?

Is ABOS or XLO more profitable?

Which has more volatility and risk, ABOS or XLO?

Do insiders & institutionals have more ownership in ABOS or XLO?

Does the media refer more to ABOS or XLO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO vs. The Competition

Xilio Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools